A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia

Kohei Hara; Akira Sakamoto; Kiyokazu Komori; Naomi Ito; Akira Saito; Ichiro Nakayama; Masumi Tomizawa; Masanari Mukai; Kazuo Takebe; Takeshi Osonoi; Yasuhisa Kuroda; Seijiro Abe; Masakichi Motomiya; Akira Watanabe; Kiyoshi Konno; Tsuueo Sayama; Kuniharu Shida; Satoshi Shinto; Satoshi Shoji; Hideo Arai; Takeshi Kawai; Atsushi Saito; Osamu Sakai; Kohya Shiba; Masaki Yoshida; Kazuhisa Okada; Hiroichi Tanimoto; Kazuo Ohara; Tetsuo Okamura; Takashi Inamatsu; Yoshishige Masuda; Fumiko Oshima; Hiroyuki Kobayashi; Kohji Narui; Eiyasu Tsuboi; Tatsuo Nakatani; Yoshitaka Nakamori; Koichiro Nakata; Fumio Matsumoto; Takeo Imai; Iwao Sakurai; Takayuki Takahashi; Masayuki Morita; Masaaki Arakawa; Koichi Wada; Takashi Kawashima; Kenichi Igarashi; Hajimu Takeda; Masanaga Takato; Shigeyuki Hoshino; Nobuki Aoki; Atsuhiko Sato; Izumi Shichi; Teiji Tamura; Yutaka Nakano; Tamaki Matsubara; Masaaki Ida; Toshiyuki Yamamoto; Kanzo Suzuki; Satoru Adachi; Toshihiko Takeuchi; Yoshimitsu Hayashi; Kazuhide Yamamoto; Fumio Miki; Rinzo Soejima; Toshiharu Matsushima; Makoto Kimura; Michio Yamakido; Kenji Hasegawa; Takafumi Tsuse; Osamu Kurimura; Kikuo Nakano; Masaaki Oune; Koji Takeda; Yoshiro Sawae; Ikuo Sumita; Takatoshi Inoue; Toshiyuki Ishimaru; Chiyuki Kawasaki; Kazuhiko Kato; Yoshiyuki Niho; Minoru Yoshida; Masayuki Nakanishi; Masanori Takayama; Kotaro Oizumi; Keizo Matsumoto; Masaru Nasu; Atsushi Saito; Yoshiteru Shigeno; Keizou Kitsukawa; Yuei Irabu; Hiroshi Fukuhara; Hiroshi Nakamura; Hajime Uema; Mitsuyoshi Nakashima; Mitsuo Kaku; Kazuyuki Sugawara

doi:10.11250/chemotherapy1953.40.1343

A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia

Kohei Hara, Akira Sakamoto, Kiyokazu Komori, Naomi Ito, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Masanari Mukai, Kazuo Takebe, Takeshi Osonoi, Yasuhisa Kuroda, Seijiro Abe, Masakichi Motomiya, Akira Watanabe, Kiyoshi Konno, Tsuueo Sayama, Kuniharu Shida, Satoshi Shinto, Satoshi Shoji, Hideo AraiTakeshi Kawai, Atsushi Saito, Osamu Sakai, Kohya Shiba, Masaki Yoshida, Kazuhisa Okada, Hiroichi Tanimoto, Kazuo Ohara, Tetsuo Okamura, Takashi Inamatsu, Yoshishige Masuda, Fumiko Oshima, Hiroyuki Kobayashi, Kohji Narui, Eiyasu Tsuboi, Tatsuo Nakatani, Yoshitaka Nakamori, Koichiro Nakata, Fumio Matsumoto, Takeo Imai, Iwao Sakurai, Takayuki Takahashi, Masayuki Morita, Masaaki Arakawa, Koichi Wada, Takashi Kawashima, Kenichi Igarashi, Hajimu Takeda, Masanaga Takato, Shigeyuki Hoshino, Nobuki Aoki, Atsuhiko Sato, Izumi Shichi, Teiji Tamura, Yutaka Nakano, Tamaki Matsubara, Masaaki Ida, Toshiyuki Yamamoto, Kanzo Suzuki, Satoru Adachi, Toshihiko Takeuchi, Yoshimitsu Hayashi, Kazuhide Yamamoto, Fumio Miki, Rinzo Soejima, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Kenji Hasegawa, Takafumi Tsuse, Osamu Kurimura, Kikuo Nakano, Masaaki Oune, Koji Takeda, Yoshiro Sawae, Ikuo Sumita, Takatoshi Inoue, Toshiyuki Ishimaru, Chiyuki Kawasaki, Kazuhiko Kato, Yoshiyuki Niho, Minoru Yoshida, Masayuki Nakanishi, Masanori Takayama, Kotaro Oizumi, Keizo Matsumoto, Masaru Nasu, Atsushi Saito, Yoshiteru Shigeno, Keizou Kitsukawa, Yuei Irabu, Hiroshi Fukuhara, Hiroshi Nakamura, Hajime Uema, Mitsuyoshi Nakashima, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

To evaluate the efficacy, safety and usefulness of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a multicenter double-blind controlled study was conducted using imipenem/cilastatin sodium (IPM/CS) as the reference drug. Patients were given 0.5 g of MEPM (the MEPM group) or 1.0 g/1.0 g of IPM/CS (the IPM/CS group) daily (b.i.d.) for 14 days as a rule. The results of evaluation by the committee were as follows: 1. Analyzed cases: Among a total of 146 cases, 113 cases were evaluated for clinical efficacy. These cases included 110 cases of bacterial pneumonia and 3 cases of lung abscess. 2. Clinical efficacy: In bacterial pneumonia, the efficacy rate was 87.5% (49/56) in the MEPM group vs. 92.6% (50/54) in the IPM/CS group. In all cases, the efficacy rate was 87.7% (50/57) in the MEPM group vs. 92.9% (52/56) in the IPM/CS group. There were no significant differences between the two groups. 3. Bacteriological response: The eradication rate was 95.8% (23/24) in the MEPM group vs. 93.1% (27/29) in the IPM/CS group. There was no significant difference between the two groups. 4. Safety: As side effects, nausea and diarrhea were noticed in 1 of 72 patients in the IPM/CS group. The incidence of abnormal laboratory findings was 36.4% (24/66) in the MEPM group vs. 27.8% (20/72) in the IPM/CS group. There was no significant difference between the two groups. Chief abnormalities were an increase in eosinophils and transient elevations of GOT and GPT. 5. Usefulness: In bacterial pneumonia the usefulness rate was 85.7% (48/56) in the MEPM group vs. 90.9% (50/55) in the IPM/CS group. In all cases the rate was 86.0% (49/57) in the MEPM group vs. 91.2% (52/57) in the IPM/CS group. There were no significant differences between the two groups. From the above results we concluded that 0.5 g/day of MEPM was as useful as 1.0 g/1.0 g/day of IPM/CS in bacterial pneumonia.

Original language	English
Pages (from-to)	1343-1364
Number of pages	22
Journal	Chemotherapy
Volume	40
Issue number	11
DOIs	https://doi.org/10.11250/chemotherapy1953.40.1343
Publication status	Published - 1992 Nov
Externally published	Yes

Keywords

Meropenem
imipenem/cilastatin sodium

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.40.1343

Cite this

Hara, K., Sakamoto, A., Komori, K., Ito, N., Saito, A., Nakayama, I., Tomizawa, M., Mukai, M., Takebe, K., Osonoi, T., Kuroda, Y., Abe, S., Motomiya, M., Watanabe, A., Konno, K., Sayama, T., Shida, K., Shinto, S., Shoji, S., ... Sugawara, K. (1992). A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia. Chemotherapy, 40(11), 1343-1364. https://doi.org/10.11250/chemotherapy1953.40.1343

A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia. / Hara, Kohei; Sakamoto, Akira; Komori, Kiyokazu; Ito, Naomi; Saito, Akira; Nakayama, Ichiro; Tomizawa, Masumi; Mukai, Masanari; Takebe, Kazuo; Osonoi, Takeshi; Kuroda, Yasuhisa; Abe, Seijiro; Motomiya, Masakichi; Watanabe, Akira; Konno, Kiyoshi; Sayama, Tsuueo; Shida, Kuniharu; Shinto, Satoshi; Shoji, Satoshi; Arai, Hideo; Kawai, Takeshi; Saito, Atsushi; Sakai, Osamu; Shiba, Kohya; Yoshida, Masaki; Okada, Kazuhisa; Tanimoto, Hiroichi; Ohara, Kazuo; Okamura, Tetsuo; Inamatsu, Takashi; Masuda, Yoshishige; Oshima, Fumiko; Kobayashi, Hiroyuki; Narui, Kohji; Tsuboi, Eiyasu; Nakatani, Tatsuo; Nakamori, Yoshitaka; Nakata, Koichiro; Matsumoto, Fumio; Imai, Takeo; Sakurai, Iwao; Takahashi, Takayuki; Morita, Masayuki; Arakawa, Masaaki; Wada, Koichi; Kawashima, Takashi; Igarashi, Kenichi; Takeda, Hajimu; Takato, Masanaga; Hoshino, Shigeyuki; Aoki, Nobuki; Sato, Atsuhiko; Shichi, Izumi; Tamura, Teiji; Nakano, Yutaka; Matsubara, Tamaki; Ida, Masaaki; Yamamoto, Toshiyuki; Suzuki, Kanzo; Adachi, Satoru; Takeuchi, Toshihiko; Hayashi, Yoshimitsu; Yamamoto, Kazuhide; Miki, Fumio; Soejima, Rinzo; Matsushima, Toshiharu; Kimura, Makoto; Yamakido, Michio; Hasegawa, Kenji; Tsuse, Takafumi; Kurimura, Osamu; Nakano, Kikuo; Oune, Masaaki; Takeda, Koji; Sawae, Yoshiro; Sumita, Ikuo; Inoue, Takatoshi; Ishimaru, Toshiyuki; Kawasaki, Chiyuki; Kato, Kazuhiko; Niho, Yoshiyuki; Yoshida, Minoru; Nakanishi, Masayuki; Takayama, Masanori; Oizumi, Kotaro; Matsumoto, Keizo; Nasu, Masaru; Saito, Atsushi; Shigeno, Yoshiteru; Kitsukawa, Keizou; Irabu, Yuei; Fukuhara, Hiroshi; Nakamura, Hiroshi; Uema, Hajime; Nakashima, Mitsuyoshi; Kaku, Mitsuo; Sugawara, Kazuyuki.

In: Chemotherapy, Vol. 40, No. 11, 11.1992, p. 1343-1364.

Research output: Contribution to journal › Article › peer-review

Hara, K, Sakamoto, A, Komori, K, Ito, N, Saito, A, Nakayama, I, Tomizawa, M, Mukai, M, Takebe, K, Osonoi, T, Kuroda, Y, Abe, S, Motomiya, M, Watanabe, A, Konno, K, Sayama, T, Shida, K, Shinto, S, Shoji, S, Arai, H, Kawai, T, Saito, A, Sakai, O, Shiba, K, Yoshida, M, Okada, K, Tanimoto, H, Ohara, K, Okamura, T, Inamatsu, T, Masuda, Y, Oshima, F, Kobayashi, H, Narui, K, Tsuboi, E, Nakatani, T, Nakamori, Y, Nakata, K, Matsumoto, F, Imai, T, Sakurai, I, Takahashi, T, Morita, M, Arakawa, M, Wada, K, Kawashima, T, Igarashi, K, Takeda, H, Takato, M, Hoshino, S, Aoki, N, Sato, A, Shichi, I, Tamura, T, Nakano, Y, Matsubara, T, Ida, M, Yamamoto, T, Suzuki, K, Adachi, S, Takeuchi, T, Hayashi, Y, Yamamoto, K, Miki, F, Soejima, R, Matsushima, T, Kimura, M, Yamakido, M, Hasegawa, K, Tsuse, T, Kurimura, O, Nakano, K, Oune, M, Takeda, K, Sawae, Y, Sumita, I, Inoue, T, Ishimaru, T, Kawasaki, C, Kato, K, Niho, Y, Yoshida, M, Nakanishi, M, Takayama, M, Oizumi, K, Matsumoto, K, Nasu, M, Saito, A, Shigeno, Y, Kitsukawa, K, Irabu, Y, Fukuhara, H, Nakamura, H, Uema, H, Nakashima, M, Kaku, M & Sugawara, K 1992, 'A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia', Chemotherapy, vol. 40, no. 11, pp. 1343-1364. https://doi.org/10.11250/chemotherapy1953.40.1343

Hara, Kohei ; Sakamoto, Akira ; Komori, Kiyokazu ; Ito, Naomi ; Saito, Akira ; Nakayama, Ichiro ; Tomizawa, Masumi ; Mukai, Masanari ; Takebe, Kazuo ; Osonoi, Takeshi ; Kuroda, Yasuhisa ; Abe, Seijiro ; Motomiya, Masakichi ; Watanabe, Akira ; Konno, Kiyoshi ; Sayama, Tsuueo ; Shida, Kuniharu ; Shinto, Satoshi ; Shoji, Satoshi ; Arai, Hideo ; Kawai, Takeshi ; Saito, Atsushi ; Sakai, Osamu ; Shiba, Kohya ; Yoshida, Masaki ; Okada, Kazuhisa ; Tanimoto, Hiroichi ; Ohara, Kazuo ; Okamura, Tetsuo ; Inamatsu, Takashi ; Masuda, Yoshishige ; Oshima, Fumiko ; Kobayashi, Hiroyuki ; Narui, Kohji ; Tsuboi, Eiyasu ; Nakatani, Tatsuo ; Nakamori, Yoshitaka ; Nakata, Koichiro ; Matsumoto, Fumio ; Imai, Takeo ; Sakurai, Iwao ; Takahashi, Takayuki ; Morita, Masayuki ; Arakawa, Masaaki ; Wada, Koichi ; Kawashima, Takashi ; Igarashi, Kenichi ; Takeda, Hajimu ; Takato, Masanaga ; Hoshino, Shigeyuki ; Aoki, Nobuki ; Sato, Atsuhiko ; Shichi, Izumi ; Tamura, Teiji ; Nakano, Yutaka ; Matsubara, Tamaki ; Ida, Masaaki ; Yamamoto, Toshiyuki ; Suzuki, Kanzo ; Adachi, Satoru ; Takeuchi, Toshihiko ; Hayashi, Yoshimitsu ; Yamamoto, Kazuhide ; Miki, Fumio ; Soejima, Rinzo ; Matsushima, Toshiharu ; Kimura, Makoto ; Yamakido, Michio ; Hasegawa, Kenji ; Tsuse, Takafumi ; Kurimura, Osamu ; Nakano, Kikuo ; Oune, Masaaki ; Takeda, Koji ; Sawae, Yoshiro ; Sumita, Ikuo ; Inoue, Takatoshi ; Ishimaru, Toshiyuki ; Kawasaki, Chiyuki ; Kato, Kazuhiko ; Niho, Yoshiyuki ; Yoshida, Minoru ; Nakanishi, Masayuki ; Takayama, Masanori ; Oizumi, Kotaro ; Matsumoto, Keizo ; Nasu, Masaru ; Saito, Atsushi ; Shigeno, Yoshiteru ; Kitsukawa, Keizou ; Irabu, Yuei ; Fukuhara, Hiroshi ; Nakamura, Hiroshi ; Uema, Hajime ; Nakashima, Mitsuyoshi ; Kaku, Mitsuo ; Sugawara, Kazuyuki. / A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia. In: Chemotherapy. 1992 ; Vol. 40, No. 11. pp. 1343-1364.

@article{93326480fab7467fb58b9f885d1de700,

title = "A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia",

abstract = "To evaluate the efficacy, safety and usefulness of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a multicenter double-blind controlled study was conducted using imipenem/cilastatin sodium (IPM/CS) as the reference drug. Patients were given 0.5 g of MEPM (the MEPM group) or 1.0 g/1.0 g of IPM/CS (the IPM/CS group) daily (b.i.d.) for 14 days as a rule. The results of evaluation by the committee were as follows: 1. Analyzed cases: Among a total of 146 cases, 113 cases were evaluated for clinical efficacy. These cases included 110 cases of bacterial pneumonia and 3 cases of lung abscess. 2. Clinical efficacy: In bacterial pneumonia, the efficacy rate was 87.5% (49/56) in the MEPM group vs. 92.6% (50/54) in the IPM/CS group. In all cases, the efficacy rate was 87.7% (50/57) in the MEPM group vs. 92.9% (52/56) in the IPM/CS group. There were no significant differences between the two groups. 3. Bacteriological response: The eradication rate was 95.8% (23/24) in the MEPM group vs. 93.1% (27/29) in the IPM/CS group. There was no significant difference between the two groups. 4. Safety: As side effects, nausea and diarrhea were noticed in 1 of 72 patients in the IPM/CS group. The incidence of abnormal laboratory findings was 36.4% (24/66) in the MEPM group vs. 27.8% (20/72) in the IPM/CS group. There was no significant difference between the two groups. Chief abnormalities were an increase in eosinophils and transient elevations of GOT and GPT. 5. Usefulness: In bacterial pneumonia the usefulness rate was 85.7% (48/56) in the MEPM group vs. 90.9% (50/55) in the IPM/CS group. In all cases the rate was 86.0% (49/57) in the MEPM group vs. 91.2% (52/57) in the IPM/CS group. There were no significant differences between the two groups. From the above results we concluded that 0.5 g/day of MEPM was as useful as 1.0 g/1.0 g/day of IPM/CS in bacterial pneumonia.",

keywords = "Meropenem, imipenem/cilastatin sodium",

author = "Kohei Hara and Akira Sakamoto and Kiyokazu Komori and Naomi Ito and Akira Saito and Ichiro Nakayama and Masumi Tomizawa and Masanari Mukai and Kazuo Takebe and Takeshi Osonoi and Yasuhisa Kuroda and Seijiro Abe and Masakichi Motomiya and Akira Watanabe and Kiyoshi Konno and Tsuueo Sayama and Kuniharu Shida and Satoshi Shinto and Satoshi Shoji and Hideo Arai and Takeshi Kawai and Atsushi Saito and Osamu Sakai and Kohya Shiba and Masaki Yoshida and Kazuhisa Okada and Hiroichi Tanimoto and Kazuo Ohara and Tetsuo Okamura and Takashi Inamatsu and Yoshishige Masuda and Fumiko Oshima and Hiroyuki Kobayashi and Kohji Narui and Eiyasu Tsuboi and Tatsuo Nakatani and Yoshitaka Nakamori and Koichiro Nakata and Fumio Matsumoto and Takeo Imai and Iwao Sakurai and Takayuki Takahashi and Masayuki Morita and Masaaki Arakawa and Koichi Wada and Takashi Kawashima and Kenichi Igarashi and Hajimu Takeda and Masanaga Takato and Shigeyuki Hoshino and Nobuki Aoki and Atsuhiko Sato and Izumi Shichi and Teiji Tamura and Yutaka Nakano and Tamaki Matsubara and Masaaki Ida and Toshiyuki Yamamoto and Kanzo Suzuki and Satoru Adachi and Toshihiko Takeuchi and Yoshimitsu Hayashi and Kazuhide Yamamoto and Fumio Miki and Rinzo Soejima and Toshiharu Matsushima and Makoto Kimura and Michio Yamakido and Kenji Hasegawa and Takafumi Tsuse and Osamu Kurimura and Kikuo Nakano and Masaaki Oune and Koji Takeda and Yoshiro Sawae and Ikuo Sumita and Takatoshi Inoue and Toshiyuki Ishimaru and Chiyuki Kawasaki and Kazuhiko Kato and Yoshiyuki Niho and Minoru Yoshida and Masayuki Nakanishi and Masanori Takayama and Kotaro Oizumi and Keizo Matsumoto and Masaru Nasu and Atsushi Saito and Yoshiteru Shigeno and Keizou Kitsukawa and Yuei Irabu and Hiroshi Fukuhara and Hiroshi Nakamura and Hajime Uema and Mitsuyoshi Nakashima and Mitsuo Kaku and Kazuyuki Sugawara",

year = "1992",

month = nov,

doi = "10.11250/chemotherapy1953.40.1343",

language = "English",

volume = "40",

pages = "1343--1364",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "11",

}

TY - JOUR

T1 - A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia

AU - Hara, Kohei

AU - Sakamoto, Akira

AU - Komori, Kiyokazu

AU - Ito, Naomi

AU - Saito, Akira

AU - Nakayama, Ichiro

AU - Tomizawa, Masumi

AU - Mukai, Masanari

AU - Takebe, Kazuo

AU - Osonoi, Takeshi

AU - Kuroda, Yasuhisa

AU - Abe, Seijiro

AU - Motomiya, Masakichi

AU - Watanabe, Akira

AU - Konno, Kiyoshi

AU - Sayama, Tsuueo

AU - Shida, Kuniharu

AU - Shinto, Satoshi

AU - Shoji, Satoshi

AU - Arai, Hideo

AU - Kawai, Takeshi

AU - Saito, Atsushi

AU - Sakai, Osamu

AU - Shiba, Kohya

AU - Yoshida, Masaki

AU - Okada, Kazuhisa

AU - Tanimoto, Hiroichi

AU - Ohara, Kazuo

AU - Okamura, Tetsuo

AU - Inamatsu, Takashi

AU - Masuda, Yoshishige

AU - Oshima, Fumiko

AU - Kobayashi, Hiroyuki

AU - Narui, Kohji

AU - Tsuboi, Eiyasu

AU - Nakatani, Tatsuo

AU - Nakamori, Yoshitaka

AU - Nakata, Koichiro

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Sakurai, Iwao

AU - Takahashi, Takayuki

AU - Morita, Masayuki

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Kawashima, Takashi

AU - Igarashi, Kenichi

AU - Takeda, Hajimu

AU - Takato, Masanaga

AU - Hoshino, Shigeyuki

AU - Aoki, Nobuki

AU - Sato, Atsuhiko

AU - Shichi, Izumi

AU - Tamura, Teiji

AU - Nakano, Yutaka

AU - Matsubara, Tamaki

AU - Ida, Masaaki

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Adachi, Satoru

AU - Takeuchi, Toshihiko

AU - Hayashi, Yoshimitsu

AU - Yamamoto, Kazuhide

AU - Miki, Fumio

AU - Soejima, Rinzo

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Yamakido, Michio

AU - Hasegawa, Kenji

AU - Tsuse, Takafumi

AU - Kurimura, Osamu

AU - Nakano, Kikuo

AU - Oune, Masaaki

AU - Takeda, Koji

AU - Sawae, Yoshiro

AU - Sumita, Ikuo

AU - Inoue, Takatoshi

AU - Ishimaru, Toshiyuki

AU - Kawasaki, Chiyuki

AU - Kato, Kazuhiko

AU - Niho, Yoshiyuki

AU - Yoshida, Minoru

AU - Nakanishi, Masayuki

AU - Takayama, Masanori

AU - Oizumi, Kotaro

AU - Matsumoto, Keizo

AU - Nasu, Masaru

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Kitsukawa, Keizou

AU - Irabu, Yuei

AU - Fukuhara, Hiroshi

AU - Nakamura, Hiroshi

AU - Uema, Hajime

AU - Nakashima, Mitsuyoshi

AU - Kaku, Mitsuo

AU - Sugawara, Kazuyuki

PY - 1992/11

Y1 - 1992/11

N2 - To evaluate the efficacy, safety and usefulness of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a multicenter double-blind controlled study was conducted using imipenem/cilastatin sodium (IPM/CS) as the reference drug. Patients were given 0.5 g of MEPM (the MEPM group) or 1.0 g/1.0 g of IPM/CS (the IPM/CS group) daily (b.i.d.) for 14 days as a rule. The results of evaluation by the committee were as follows: 1. Analyzed cases: Among a total of 146 cases, 113 cases were evaluated for clinical efficacy. These cases included 110 cases of bacterial pneumonia and 3 cases of lung abscess. 2. Clinical efficacy: In bacterial pneumonia, the efficacy rate was 87.5% (49/56) in the MEPM group vs. 92.6% (50/54) in the IPM/CS group. In all cases, the efficacy rate was 87.7% (50/57) in the MEPM group vs. 92.9% (52/56) in the IPM/CS group. There were no significant differences between the two groups. 3. Bacteriological response: The eradication rate was 95.8% (23/24) in the MEPM group vs. 93.1% (27/29) in the IPM/CS group. There was no significant difference between the two groups. 4. Safety: As side effects, nausea and diarrhea were noticed in 1 of 72 patients in the IPM/CS group. The incidence of abnormal laboratory findings was 36.4% (24/66) in the MEPM group vs. 27.8% (20/72) in the IPM/CS group. There was no significant difference between the two groups. Chief abnormalities were an increase in eosinophils and transient elevations of GOT and GPT. 5. Usefulness: In bacterial pneumonia the usefulness rate was 85.7% (48/56) in the MEPM group vs. 90.9% (50/55) in the IPM/CS group. In all cases the rate was 86.0% (49/57) in the MEPM group vs. 91.2% (52/57) in the IPM/CS group. There were no significant differences between the two groups. From the above results we concluded that 0.5 g/day of MEPM was as useful as 1.0 g/1.0 g/day of IPM/CS in bacterial pneumonia.

AB - To evaluate the efficacy, safety and usefulness of meropenem (MEPM), a new carbapenem antibiotic for injection, in bacterial pneumonia, a multicenter double-blind controlled study was conducted using imipenem/cilastatin sodium (IPM/CS) as the reference drug. Patients were given 0.5 g of MEPM (the MEPM group) or 1.0 g/1.0 g of IPM/CS (the IPM/CS group) daily (b.i.d.) for 14 days as a rule. The results of evaluation by the committee were as follows: 1. Analyzed cases: Among a total of 146 cases, 113 cases were evaluated for clinical efficacy. These cases included 110 cases of bacterial pneumonia and 3 cases of lung abscess. 2. Clinical efficacy: In bacterial pneumonia, the efficacy rate was 87.5% (49/56) in the MEPM group vs. 92.6% (50/54) in the IPM/CS group. In all cases, the efficacy rate was 87.7% (50/57) in the MEPM group vs. 92.9% (52/56) in the IPM/CS group. There were no significant differences between the two groups. 3. Bacteriological response: The eradication rate was 95.8% (23/24) in the MEPM group vs. 93.1% (27/29) in the IPM/CS group. There was no significant difference between the two groups. 4. Safety: As side effects, nausea and diarrhea were noticed in 1 of 72 patients in the IPM/CS group. The incidence of abnormal laboratory findings was 36.4% (24/66) in the MEPM group vs. 27.8% (20/72) in the IPM/CS group. There was no significant difference between the two groups. Chief abnormalities were an increase in eosinophils and transient elevations of GOT and GPT. 5. Usefulness: In bacterial pneumonia the usefulness rate was 85.7% (48/56) in the MEPM group vs. 90.9% (50/55) in the IPM/CS group. In all cases the rate was 86.0% (49/57) in the MEPM group vs. 91.2% (52/57) in the IPM/CS group. There were no significant differences between the two groups. From the above results we concluded that 0.5 g/day of MEPM was as useful as 1.0 g/1.0 g/day of IPM/CS in bacterial pneumonia.

KW - Meropenem

KW - imipenem/cilastatin sodium

UR - http://www.scopus.com/inward/record.url?scp=0027102930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027102930&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.1343

DO - 10.11250/chemotherapy1953.40.1343

M3 - Article

AN - SCOPUS:0027102930

VL - 40

SP - 1343

EP - 1364

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 11

ER -

A comparative study of meropenem and imipenem/cilastatin sodium in bacterial pneumonia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this